Consensus Avid Bioservices, Inc.

Equities

CDMO

US05368M1062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.35 ^USD	+0.41%		+15.02%	+13.08%

Apr. 24	Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
Apr. 19	North American Morning Briefing : Stock Futures -2-	DJ

Evolution of the average Target Price on Avid Bioservices, Inc.

Price target over the last 5 years

History of analyst recommendation changes

887a65.pbRtD20xyIhkCqm9xXpVYembx6Ni6o0vNZO_wMwUT40.6uchZxd0g8IoXu3srkMiG5DtmJIhtetNf6HyrbVfJuHvgwJADGCmzi46-A~d61a192b650f6237bee24d1efd6ad4bc

Analyst Recommendations on Avid Bioservices, Inc.

Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating	Mar. 11	MT
Craig-Hallum Adjusts Avid Bioservices' Price Target to $16 From $22, Maintains Buy Rating	Dec. 08	MT
KeyBanc Cuts Price Target on Avid Bioservices to $14 From $20, Maintains Overweight Rating	Dec. 08	MT
RBC Cuts Price Target on Avid Bioservices to $7 From $15, Cites Slower Revenue Growth Assumptions Amid 'Challenging' Demand Backdrop; Outperform Kept	Dec. 08	MT
William Blair Initiates Coverage on Avid Bioservices with Market Perform Rating	23-09-28	MT
RBC Cuts Price Target on Avid Bioservices to $15 From $17 Amid 'Mixed' Fiscal Q1 Results, Keeps Outperform Rating	23-09-08	MT
Stephens Adjusts Avid Bioservices Price Target to $20 From $24, Maintains Overweight Rating	23-06-22	MT
Craig Hallum Adjusts Avid Bioservices Price Target to $22 From $25, Maintains Buy Rating	23-06-22	MT
RBC Cuts Price Target on Avid Bioservices to $17 From $20, Cites Softer-Than-Expected Revenue Guidance; Outperform Kept	23-06-22	MT
Avid Bioservices Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $20 After Fiscal Q3 Beat; Shares Up Pre-Bell	23-03-14	MT
RBC Cuts Price Target on Avid Bioservices to $20 From $22, Notes Fiscal Q2 Adjusted EBITDA Miss, Keeps Outperform Rating	22-12-07	MT
RBC Cuts Price Target on Avid Bioservices to $22 From $32, Citing Lower Group Multiples, Maintains Outperform Rating	22-06-30	MT
Craig-Hallum Lowers Price Target for Avid Bioservices to $30 From $35, Maintains Buy Rating	22-03-09	MT
Stephens Adjusts Avid Bioservices' Price Target to $28 from $31, Keeps Overweight Rating	22-03-09	MT
Craig-Hallum Adjusts Price Target on Avid Bioservices to $35 From $29, Keeps Buy Rating	21-12-08	MT
RBC Lifts Price Target on Avid Bioservices to $32 From $27, Calls Fiscal Q2 'Impressive Quarter for New Business Wins,' Keeps Outperform	21-12-08	MT
KeyBanc Downgrades Avid Bioservices to Sector Weight From Overweight	21-12-08	MT
AVID BIOSERVICES : Craig-Hallum Adjusts Price Target on Avid Bioservices to $29 From $21, Maintains Buy Rating	21-06-30	MT
AVID BIOSERVICES : KeyBanc Adjusts Avid Bioservices' Price Target to $28 From $22, Reiterates Overweight Rating	21-06-30	MT
AVID BIOSERVICES : RBC Raises Price Target on Avid Bioservices to $27 From $21 After Fiscal Q4 Revenue Beat, Maintains Outperform Rating	21-06-30	MT
AVID BIOSERVICES : Initiated at Outperform by RBC, Price Target Set at $21	21-03-17	MT
AVID BIOSERVICES : KeyBanc Initiates Avid Bioservices at Overweight with $12 Price Target	20-11-10	MT